Pure Global
NCT06345482

A Study of MHB039A for Advanced Solid Tumor

A Phase I/II Study of MHB039A for Advanced Solid Tumor to Evaluate the Efficacy and Safety
Minghui Pharmaceutical (Hangzhou) Ltd·Phase 1/2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Advanced Solid Tumor
Drug/Device/Intervention
MHB039A
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Minghui Pharmaceutical (Hangzhou) Ltd
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 1/2
Start date
Apr 01, 2024
End date
Jun 01, 2029
Enrollment
196 participants
Primary outcome

Incidence of participants with adverse events (AE),Number of participants with dose-limiting toxicity (DLT)

Summary

Phase I/II open label, multicenter study to evaluate the efficacy and safety of MHB039A in
 advanced malignant tumors.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06345482
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06345482 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Minghui Pharmaceutical (Hangzhou) Ltd and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 196 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.